EUCTR2005-003521-13-DE进行中（未招募）不适用
Double-blind, randomized, parallel-group, dose ranging, multi-center study to evaluate the efficacy and safety of 2.5, 10, 35 and 50 mg AVE7688 once daily, using 100 mg losartan-potassium once daily as calibrator, for 12 months treatment, in patients with mild to moderate hypertension - RAVEL-1
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,730
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients, 18 years of age or older, with mild-to-moderate, treated or untreated, essential hypertension, as defined by the JNC VII guidelines, who meet the following BP eligibility criteria:
- •- At the first qualifying visit in the placebo lead-in phase (either visit P2 or P3), mean SeSBP =140 mm Hg and <180 mm Hg and mean SeDBP =90 mm Hg and <110 mm Hg (mean of at least 3 readings)
- •- At the second qualifying visit in the placebo lead-in phase (either visit P3 or P4 separated from the first qualifying visit by at least 1 week), SeSBP =140 mm Hg and <180 mm Hg and mean SeDBP =90 mm Hg and <110 mm Hg (mean of at least 3 readings). If the patient does not meet the criteria at the second qualifying visit, he or she will be excluded from randomization.
- •-The patient can be included in the study only when the variability between the mean BP measurements on the two consecutive qualifying visits (either P2 and P3 or P3 and P4 (if applicable)) is less or equal than 7 mm Hg for SeDBP.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Criteria related to study methodology:
- •- Refusal or inability to give informed consent
- •- Patients who have previously been treated with AVE7688
- •- Patients who cannot stop their anti-hypertensive treatment (e.g., ACE-I (angiotensin convertin enzyme inhibitor), ARB (angiotensin receptor blocker), CCB (calcium channel blocker), diuretics, AB (alpha blocker), BB (beta blocker), Hydralazine, Rauwolfia alkaloids
- •- Known history of secondary hypertension, including patients with endocrine disorders such as pheochromocytoma, active hyperthyroidism, or untreated hypothyroidism
- •- Severe hypertension, defined as SeSBP =180 mm Hg or SeDBP =110 mm Hg
- •- Women of child bearing potential (i.e. female patients who are not postmenopausal or surgically sterile), who have a positive serum pregnancy test, or who do not agree to use an accepted method of contraception
- •- Women who are breast feeding
- •- Patients with non-cardiac progressive fatal disease
- •- Patients with immunological or hematological disorders
- •- Requirement for concomitant treatment that could bias the primary evaluation, e.g. long-term treatment with anti-psychotic compounds or long-term steroid use
- •- Unstable insulin-dependent diabetes mellitus
- •- History of stroke, intracranial hemorrhage or transitory ischemic attack within the previous year
- •- Likelihood of poor compliance both with treatment and study design, including social and geographical reasons
- •- Patient is the investigator, sub-investigator, research assistant, pharmacist, study coordinator, or other staff member or relative thereof directly involved in the conduct of the study
- •- Administration of any investigational drug within the preceding 30 days. Investigational drug is defined as any agent (placebo or active drug) dispensed as part of a research study
- •- Abuse of drugs or alcoholic beverages within 1 year prior to the start of the study
- •- Patients taking herbal or dietary compounds that have the potential to influence blood pressure
- •Criteria related to ACE-inhibition
- •- Contraindications to losartan-potassium as per local package insert
- •- History of hypersensitivity or angioedema with ACE inhibitors or NEP inhibitors, patients with hereditary or idiopathic angioedema, patients with allergic reaction in which urticaria or angioedema was the manifestation
- •- Impaired hepatic function (i.e., AST and/or ALT >1.5 x upper limit of normal range)
- •- Known unilateral or bilateral renal artery stenosis
- •- Serum potassium = 5.5 mmol/L
- •- Impaired renal function (i.e. calculated creatinine clearance < 50 ml/min)
研究者
相似试验
进行中（未招募）
不适用
Double-blind, randomized, parallel-group, dose ranging, multi-center study to evaluate the efficacy and safety of 2.5, 10, 35 and 50 mg AVE7688 once daily, using 100 mg losartan-potassium once daily as calibrator, for 12 months treatment, in patients with mild to moderate hypertensioEUCTR2005-003521-13-PTAventis Pharmaceuticals Inc.1,730
进行中（未招募）
不适用
Double-blind, randomized, parallel-group, dose ranging, multi-center study to evaluate the efficacy and safety of 2.5, 10, 35 and 50 mg AVE7688 once daily, using 100 mg losartan-potassium once daily as calibrator, for 12 months treatment, in patients with mild to moderate hypertension. - NDMILD TO MODERARATE HYPERTENSIONMedDRA version: 6.1Level: PTClassification code 10015488EUCTR2005-003521-13-ITAventis Pharma Recherche De ve loppement1,730
进行中（未招募）
不适用
A study for the investigation of safety of different doses of IBP-9414 that are randomly assigned to preterm infantsPrevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 gramsEUCTR2015-004228-70-SEInfant Bacterial Therapeutics AB120
进行中（未招募）
不适用
Clinical study to evaluate the use of a new VR506 inhaler to treate severe asthmaAsthmaEUCTR2011-005030-19-ESVectura Limited174
进行中（未招募）
不适用
Clinical study to evaluate the use of a new VR506 inhaler to treate severe asthmaAsthmaMedDRA version: 15.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-005030-19-PLVectura Limited175